Defects in apoptotic signaling including overexpression of BCL2 antiapoptotic proteins contribute to increased survival of diffuse large B-cell lymphoma (DLBCL) and might result in selection of resistant clones. Agents specifically blocking the 
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype in the western hemisphere. According to the cell-of-origin (COO) determined by gene expression profiling (GEP) or several immunohistochemistry (IHC)-based algorithms DLBCL can be divided into two prognostically different groups: germinal center Bcell-like (GCB) DLBCLs, and activated B-cell-like (ABC) DLBCLs, where ABCDLBCLs are associated with more adverse prognosis (1-3).
Defects in apoptotic signaling represent one of the hallmarks of lymphoid malignancies (4) . BCL2 belongs to key regulators of intrinsic apoptosis triggered in response to severe DNA damage or other cellular stresses. Overexpression of BCL2 provides aberrant survival advantage for lymphoma cells and is believed to play one of the key roles in chemoresistance (5) (6) . Overexpression of BCL2 was repeatedly associated with more adverse outcome to standardly used chemotherapy (7) (8) (9) (10) .
Recently, a phase 1 dose-escalation study with a highly-specific BCL2 inhibitor ABT-199 demonstrated excellent anti-tumor efficacy in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), both of which are known to ubiquitously overexpress BCL2 protein. In contrast, its efficacy in DLBCL was less obvious, as 4 out of 8 enrolled patients experienced progression on study treatment (11) . Possible therapeutic application of ABT-199 in the treatment of DLBCL thus needs further investigation.
Significance of the other two BCL2 family members, MCL1 and BCL-XL, for the survival of DLBCL remains less clear. Wenzel et al reported higher expression of MCL1 in ABC-compared to GCB-DLBCLs (12) . The authors suggested that MCL1 might represent a new drug target in this subgroup of DLBCL, which was partially demonstrated in the recent publication by Li et al (13) .
Homoharringtonine (HHT, Synribo TM ), originally a plant alkaloid, was recently approved for the therapy of chronic myeloid leukemia (CML) resistant to tyrosinekinase inhibitors (14). Molecular mechanisms of anti-tumor activity of HHT appear to be multifactorial, and include downregulation of short-lived proteins including MCL1 (15). Currently there is no knowledge on its antitumor activity in lymphomas.
In this study we investigated the significance of BCL2, MCL1 and BCL-XL for the survival of DLBCL and the outcome of their targeting by various approaches. 
MATERIALS AND METHODS

DLBCL cell lines
Cell lines were cultured in Iscove's modified Dulbecco's medium (IMDM) supplemented with 15% fetal bovine serum (FBS) and 1% penicillin/streptomycin.
With the exception of HBL-1, TMD8 and OCI-Ly2 (kindly provided by Dr. Francisco Hernandez-Ilizaliturri (Roswell Park Cancer Institute, Buffallo, NY, USA), all the remaining cell lines were purchased from the cell banks (DSMZ, ATCC) and were passaged for fewer than 6 months since their receipt. According to the information provided by the cell banks, the cell lines were authenticated by PCR of short tandem repeat markers confirming unique DNA profiles. HBL-1 and TMD8 cells were confirmed to carry heterozygous missense mutations of CD79B gene Y196F and Y196H, respectively. OCI-Ly2 cell line has not been authenticated for lack of relevant molecular markers. COO of HBL1 and OCI-Ly2 murine xenografts was confirmed to be of ABC and GCB immunophenotype, respectively (Hans algorithm, data not shown). UPF4D cell line was derived in our laboratory from a patient with treatment-refractory GCB-DLBCL. Sequencing of IGHV confirmed clonal identity of UPF4D with the primary DLBCL cells, from which it was established (data not shown).
Reagents
ABT-199, ABT-737 and HHT were purchased from Selleck Chemicals and R&D
Systems.
Cell proliferation/survival assays and apoptosis measurement DLBCL cells were plated at a cell density of 5.000 cells / 0.3 ml and exposed to ABT-199 or HHT. WST-8-based Quick Cell Proliferation Assay Kit (BioVision) was used according to the manufacturer´s instructions. Number of apoptotic cells was determined by flow cytometry (BD FACS Canto II) using Annexin V (BD Biosciences). CompuSyn version 1.0 software (ComboSyn, Paramus, NJ, USA) was used to assess drug synergism between ABT-199 and HHT. Combination index (CI) was calculated for different drug combinations (16 
Real-time RT-PCR
Total RNA was isolated from cell lines in Ribozol (Amresco) using phenolchloroform extraction and from formalin-fixed paraffin-embedded (FFPE) tissue samples using High Pure RNA Paraffin Kit (Roche Diagnostics GmbH) according to the manufacturer´s instructions. cDNA synthesis was carried out from 1 µg of total RNA with High-Capacity cDNA Reverse Transcription Kit (random primers) (Applied Biosystems). Real-time RT-PCR was performed using TaqMan Gene Expression Assays (BCL2: Hs00608023_m1, MCL1: Hs01050896_m1, BCL-XL: Hs00236329_m1) on ABI 7900HT detection system (Applied Biosystems). The reference gene was GAPDH (Hs02758991_g1).
Western blotting (WB)
WB was performed as previously described (17) . Antibodies were obtained from Cell 
Immunoprecipitation
Cells were lysed in non-denaturating lysis buffer (1% (W/v) Triton X-100, 50 mM Tris-HCl (pH= 7.4), 300 mM NaCl, 5 mM EDTA, 0,02% (W/v) sodium azide supplemented with Protease inhibitor cocktail, 2 μM DTT and 1 mM PMSF for 20 minutes and centrifuged (16.000 x g, 4°C, 15 min). Protein concentrations of cell extracts were determined by Pierce BCA Protein Assay Kit and equal amount of protein samples were precleared with protein A-Sepharose bead slurry (SigmaAldrich) for 3 x 30 minutes at 4°C, split in half and incubated with a specific antibody (MCL1 (Santa Cruz, sc-819), BIM (Cell Signaling, 2933) or an isotype control (rabbit polyclonal IgG, Calbiochem) bound to protein A-Sepharose beads for 1 hour at 4°C.
Immunoprecipitates were centrifuged (16.000 x g, 4°C, 5 s), washed 3 times in wash buffer (0.1% Triton X-100, 50mM Tris-HCl (pH= 7.4), 300 mM NaCl, 5 mM EDTA, 0.02% sodium azide), resuspended in sample buffer, denaturated for five minutes at 95°C, resolved on a 10, 12 or 15% SDS-PAGE and analyzed by immunoblotting.
Experimental therapy of DLBCL xenografts
In vivo studies were approved by the institutional Animal Care and Use Committee. 
Statistical analysis
The strength of linear relationship between the expression levels of BCL2, BCL-XL and MCL1 proteins (evaluated by densitometry of western blots) and the sensitivity to 
BCL2-negative DLBCL cell lines are resistant to ABT-199
Significant differences in BCL2 expression in the analyzed DLBCL cell lines prompted us to examine whether they are also reflected in the sensitivity of these cells proteins. Our results also suggest a weak negative correlation between the expression levels of MCL1 and the sensitivity to ABT-199 (r P = -0.11; r S = -0.284; p= 0.254; 95% CI from -0.699 to 0.261). Non-rejection of the null hypothesis at 5% significance level is presumably caused by the low power of the test (small sample size) rather than the absence of an association between the analyzed variables. (Figure 3A,D,G,J,M,P) . In all apoptosis assays, the clones with manipulated expression of BCL2 proteins were compared to the corresponding controls.
MCL1-targeting agent homoharringtonine (HHT) is anti-proliferative and proapoptotic in most DLBCL cell lines
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BCL2
Knockdown of BCL2 expression in OCI-Ly2 cells that are highly sensitive to ABT-199 was lethally toxic (repeated attempts, data not shown). 0.03612< CI < 0.25985) (16) .
BH3-only proteins bound to MCL1 determine MCL1-dependence of DLBCL cell lines
HHT in combination with ABT-199 significantly prolongs overall survival of primary DLBCL xenograft-bearing mice compared to single agent approaches
To confirm the observed anti-DLBCL synergism between HHT and ABT-199 in vivo we used two primary cell-based mouse xenograft models of DLBCL known to coexpress BCL2 and MCL1 proteins (established in our laboratory and designated KTC and NOVA-313) ( Figure 5C ). It must be emphasized that the primary end-point of 
DISCUSSION
Targeted inhibition of BCL2 with its highly selective inhibitor ABT-199 recently emerged as a promising treatment strategy for some B-cell malignancies such as CLL and MCL, but its possible application in DLBCL seems to be less obvious (24) . It must be emphasized that a substantial part of DLBCL cases lack BCL2 by standard IHC analysis (10) . Moreover, the expression status of BCL2 in the reported clinical trials with ABT-199 was not specified (11) .
We analyzed 18 established DLBCL cell lines as relevant substitutes for primary DLBCL samples to evaluate the role of major anti-apoptotic proteins BCL2, MCL1, and BCL-XL in the survival of DLBCL. As previously suggested we also demonstrated that the lack of BCL2 protein expression was associated with resistance to (Figure 1, Supplemental Figure 3) . In translation, the data indicate that ABT-199-based therapy should be avoided in BCL2-negative DLBCL patients. 
previously published data (20) , that inhibition of BCL2, and not BCL-XL, was the principal molecular mechanism of cell death in the sensitive cell lines. Figure 1A-B)(12-13) . To confirm our data the protein expression of MCL1 in the cell lines was verified using another anti-MCL1 antibody with the same results (data not shown). We also confirmed that IHC analysis of subcutaneous murine xenografts of selected DLBCL cell lines for MCL1 protein expression corresponded well with western blot analysis of the cell lysates (Supplemental Table 1 ). We must, however, emphasize that both western blot and IHC are semi-quantitative methods, and potential differences in the technical aspects and interpretation of the data might play central roles in the observed differences between our results and the work of other groups. Figure 6) . We could deduce from these results that acquired overexpression of BCL-XL might suppress MCL1-dependence of DLBCL cells.
Overexpression of BCL2 in BCL2-negative DLBCL cell lines (UPF4D, SU-DHL-5) did not affect resistance of the derived clones to ABT-199, which is in concordance with the previous communication by Deng et al for . On the other hand, the upregulated BCL2 protein significantly decreased apoptosis induced by HHT (Figure 3) . We proved that transgenic expression of BCL2 can serve as a buffer for apoptosis-triggering protein BIM after it is released from MCL1 as a result of MCL1 downregulation upon exposure of the cells to HHT (Figure 4B ). In addition, overexpression of BCL2 might also buffer the additional proapoptotic activities induced by HHT (specified in Supplemental Figure 5 ). The data thus at least partially explain molecular basis of the observed trend to increased sensitivity of Our data thus indicate that DLBCL can be divided into BCL2-dependent and/or MCL1-dependent subgroups (Figure 6 ). While the BCL2-positive subgroup comprises both BCL2-and MCL1-dependent cells that might be targeted by ABT-199, HHT or the combination of both agents (with a marked synergistic efficacy), the BCL2-negative DLBCL subgroup appears to be predominantly (if not exclusively) MCL1-dependent. As previously proposed by others, our data thus confirmed that MCL1 indeed is a promising druggable target in DLBCL. In our study we used HHT to target MCL1. In their recent publication in Leukemia Li et al used other anti-cancer agents to downregulate MCL1 including cyclin-dependent kinase inhibitor dinaciclib and standardly used cytostatics (doxorubicin, etoposide, cytarabine) (13) . However, all these agents (like HHT used in our study) have broad spectra of anti-cancer activities that go far beyond downregulation of MCL1. Nevertheless our data suggest that HHT works specifically through inhibition of MCL1 at least in the HHT-highsensitive DLBCL cells.
In conclusion, ABT-199 might still prove effective anti-DLBCL agent, but only in the subgroup of BCL2-positive DLBCL. On the other hand, HHT appears to be a promising anti-lymphoma agent for DLBCL irrespective of BCL2 expression status, despite the fact that it after all appears more effective in the BCL2-negative DLBCL.
Most importantly, the concurrent inhibition of BCL2 and MCL1 (in our hands by ABT-199 and HHT) induces significant synthetic lethality in most BCL2-positive DLBCL cell lines (Figure 5A-B) , and might represent a new treatment strategy for this subgroup of DLBCL as confirmed also in vivo on murine xenograft models based on xenotransplantation of primary DLBCL cells co-expressing BCL2 and MCL1 ( Figure 5C-E) . As HHT is a clinically approved anti-tumor drug and ABT-199 is in advanced phases of clinical testing in diverse malignancies, our data might have direct implications for novel concepts of experimental therapy of DLBCL targeted at BCL2 and/or MCL1 using HHT and ABT-199, single-agent or in combination.
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